SCOPE 2023: Synopsis of Biospecimen Sample Management Presentation
Hope Meely, chief clinical officer at Slope, provides a brief summary of her SCOPE presentation revolving around biospecimen collection.
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Hope Meely, chief clinical officer at Slope, explains why biospecimens within the precision and personalized medicine spaces have become so valuable. Meely is coming off her conference presentation, "The Hidden Regulatory Risk from Sample Management — What Should You Be Aware of?”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
